News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
269,388 Results
Type
Article (14353)
Company Profile (283)
Press Release (254752)
Section
Business (80528)
Career Advice (156)
Deals (13419)
Drug Delivery (36)
Drug Development (50671)
Employer Resources (31)
FDA (5828)
Job Trends (5210)
News (146020)
Policy (10162)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (956)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21851)
ALS (54)
Alzheimer's disease (814)
Antibody-drug conjugate (ADC) (79)
Approvals (5833)
Artificial intelligence (101)
Autoimmune disease (7)
Automation (5)
Bankruptcy (104)
Best Places to Work (4625)
BIOSECURE Act (5)
Biosimilars (36)
Biotechnology (232)
Bladder cancer (40)
Brain cancer (20)
Breast cancer (132)
Cancer (1184)
Cardiovascular disease (93)
Career advice (135)
Career pathing (2)
CAR-T (102)
Cell therapy (292)
Cervical cancer (5)
Clinical research (40903)
Collaboration (465)
Compensation (201)
Complete response letters (13)
COVID-19 (1039)
CRISPR (33)
C-suite (130)
Cystic fibrosis (75)
Data (1228)
Denatured (11)
Depression (27)
Diabetes (113)
Diagnostics (1311)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (74)
Drug pricing (27)
Drug shortages (4)
Duchenne muscular dystrophy (64)
Earnings (29791)
Editorial (16)
Employer branding (4)
Employer resources (29)
Events (48672)
Executive appointments (379)
FDA (6389)
Featured Employer (34)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (435)
Gene editing (81)
Generative AI (9)
Gene therapy (213)
GLP-1 (347)
Government (1092)
Grass and pollen (2)
Guidances (17)
Healthcare (6802)
Huntington's disease (21)
IgA nephropathy (18)
Immunology and inflammation (72)
Indications (16)
Infectious disease (1094)
Inflammatory bowel disease (109)
Inflation Reduction Act (8)
Influenza (16)
Intellectual property (53)
Interviews (18)
IPO (7329)
IRA (11)
Job creations (879)
Job search strategy (129)
Kidney cancer (6)
Labor market (4)
Layoffs (201)
Leadership (2)
Legal (1421)
Liver cancer (30)
Lung cancer (168)
Lymphoma (79)
Machine learning (1)
Management (7)
Manufacturing (108)
MASH (48)
Medical device (2696)
Medtech (2697)
Mergers & acquisitions (6350)
Metabolic disorders (340)
Multiple sclerosis (46)
NASH (14)
Neurodegenerative disease (53)
Neuropsychiatric disorders (22)
Neuroscience (1152)
NextGen: Class of 2025 (2065)
Non-profit (910)
Northern California (1432)
Now hiring (21)
Obesity (174)
Opinion (99)
Ovarian cancer (50)
Pain (38)
Pancreatic cancer (48)
Parkinson's disease (95)
Partnered (6)
Patents (99)
Patient recruitment (57)
Peanut (35)
People (25752)
Pharmaceutical (49)
Pharmacy benefit managers (5)
Phase I (14396)
Phase II (19015)
Phase III (12067)
Pipeline (578)
Podcasts (42)
Policy (33)
Postmarket research (863)
Preclinical (6032)
Press Release (30)
Prostate cancer (50)
Psychedelics (35)
Radiopharmaceuticals (211)
Rare diseases (263)
Real estate (1456)
Recruiting (12)
Regulatory (8586)
Reports (14)
Research institute (989)
Resumes & cover letters (18)
Rett syndrome (3)
RNA editing (2)
RSV (10)
Schizophrenia (52)
Series A (85)
Series B (51)
Service/supplier (1)
Sickle cell disease (37)
Southern California (1262)
Special edition (10)
Sponsored (11)
Startups (1984)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (31)
United States (11317)
Vaccines (199)
Venture capitalists (27)
Webinars (7)
Weight loss (99)
Women's health (14)
Worklife (2)
Date
Today (27)
Last 7 days (410)
Last 30 days (1598)
Last 365 days (20356)
2025 (3564)
2024 (20721)
2023 (22604)
2022 (27054)
2021 (28124)
2020 (23666)
2019 (16585)
2018 (12044)
2017 (13932)
2016 (12012)
2015 (14638)
2014 (10607)
2013 (7614)
2012 (7673)
2011 (7755)
2010 (7523)
Location
Africa (150)
Alabama (37)
Alaska (2)
Arizona (56)
Arkansas (5)
Asia (17353)
Australia (2931)
California (3253)
Canada (1004)
China (290)
Colorado (126)
Connecticut (136)
Delaware (84)
Europe (37503)
Florida (379)
Georgia (95)
Idaho (16)
Illinois (206)
India (7)
Indiana (83)
Iowa (1)
Japan (65)
Kansas (58)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (425)
Massachusetts (2574)
Michigan (68)
Minnesota (134)
Mississippi (1)
Missouri (22)
Montana (19)
Nebraska (4)
Nevada (14)
New Hampshire (19)
New Jersey (823)
New Mexico (11)
New York (904)
North Carolina (500)
North Dakota (4)
Northern California (1432)
Ohio (102)
Oklahoma (8)
Oregon (22)
Pennsylvania (614)
Puerto Rico (1)
Rhode Island (13)
South America (245)
South Carolina (3)
Southern California (1262)
Tennessee (24)
Texas (365)
Utah (45)
Virginia (66)
Washington D.C. (27)
Washington State (307)
Wisconsin (14)
269,388 Results for "monte rosa therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Collaboration
Novartis Inks Potential $2.2B Molecular Glue Deal With Monte Rosa
The Swiss pharma is paying $150 million upfront to gain rights to Monte Rosa’s VAV1-targeting molecular glue degraders, led by a Phase I candidate which holds therapeutic promise for immune-mediated diseases.
October 28, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
February 25, 2025
·
1 min read
Press Releases
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
January 13, 2025
·
14 min read
Press Releases
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
·
1 min read
Press Releases
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
November 27, 2024
·
1 min read
Press Releases
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
December 13, 2024
·
3 min read
Business
Monte Rosa Therapeutics Announces Leadership Team Promotions
Monte Rosa Therapeutics, Inc. today announced three leadership team promotions effective immediately: Sharon Townson, Ph.D., to Chief Scientific Officer; Phil Nickson, Ph.D., J.D., to Chief Business and Legal Officer; and Jennifer Champoux to Chief Operating Officer.
May 30, 2024
·
3 min read
Press Releases
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
November 13, 2024
·
1 min read
Genetown
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
Monte Rosa Therapeutics, Inc. today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 3:30 p.m. ET.
May 30, 2024
·
1 min read
Deals
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
Monte Rosa Therapeutics, Inc. today announced the pricing of an underwritten public offering of 10,638,476 shares of its common stock at a public offering price of $4.70 per share.
May 16, 2024
·
5 min read
1 of 26,939
Next
